innerbuddies gut microbiome testing

Gut Microbiome and IBS-M (Mixed IBS): How Gut Bugs Influence Symptoms

If you live with IBS-M (mixed bowel habit IBS), you may notice symptoms that flip between constipation and diarrhea—often accompanied by bloating and abdominal pain. One of the biggest drivers behind this “mixed” pattern can be changes in your gut microbiome, the trillions of microbes that help break down food, maintain the intestinal barrier, and communicate with your gut and brain.

In a healthy gut, microbiome diversity and balance support steady digestion and smoother bowel movements. But in IBS-M, researchers often find signs of dysbiosis—an imbalance in the types and functions of gut bacteria and other microbes. This can alter fermentation of carbohydrates, shifting gas production and stool consistency. It may also affect the production of key microbial byproducts (including short-chain fatty acids), which help regulate motility, inflammation, and the sensitivity of the gut lining.

Your microbiome also plays a central role in the gut–brain connection. When dysbiosis changes immune activity, gut barrier function, and nerve signaling, the gut can become more reactive to normal triggers—like stress, certain foods, or meal timing. The result is a cycle where symptom flare-ups can further influence the microbiome, making relief more challenging. The good news: targeted lifestyle and nutrition strategies can support a healthier microbial ecosystem and help calm IBS-M symptoms over time.

Take a Gut Microbiome Test for IBS-M Insights Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

IBS-M — mixed bowel habit IBS

Irritable bowel syndrome with mixed bowel habits (IBS-M) is a common functional gut disorder characterized by alternating constipation and diarrhea, along with cramping, bloating, urgency, and mucus in the stool. Unlike inflammatory bowel diseases, IBS-M usually lacks structural damage, and symptoms fluctuate with stress, sleep, hormones, medications, infections, and certain foods. Increasingly, IBS-M is understood through gut–brain and microbiome interactions, where the microbiota influences motility, sensation, and barrier function.

The IBS-M microbiome often shows dysbiosis and shifts in microbial composition and function rather than simply being more or less diverse. Beneficial bacteria such as Faecalibacterium prausnitzii, Roseburia, Eubacterium rectale, Bifidobacterium species, and Akkermansia muciniphila are commonly reduced, while taxa like Bacteroides, Escherichia–Shigella, Ruminococcus gnavus/torques, Streptococcus, and Enterococcus may be elevated. Altered carbohydrate fermentation changes gas production and luminal osmotics, and imbalanced short-chain fatty acid production can impact barrier integrity, motility, and visceral sensitivity. Through the gut–brain axis and immune signaling, these microbial shifts can amplify visceral hypersensitivity and drive the fluctuating symptoms of IBS-M.

Testing the microbiome can help tailor management by identifying fermentation and metabolite patterns that underlie symptoms, guiding dietary strategies (such as soluble fiber with gradual increases and prebiotic use) and microbiome-supportive interventions. The InnerBuddies test links symptom patterns to microbiome function, offering insights into drivers of bloating, distension, and alternating stool consistency, and supporting a personalized plan to stabilize stool form and reduce distension by focusing on microbial balance and gut–brain signaling.

  • Depletion of butyrate-producing bacteria (Faecalibacterium prausnitzii, Roseburia spp., Eubacterium rectale, Anaerostipes hadrus) reduces SCFA supply, weakens gut barrier, and contributes to bloating, cramping, and unstable stool in IBS-M.
  • Low levels of Akkermansia muciniphila are linked to impaired mucus layer health and gut barrier function, potentially worsening IBS-M symptoms.
  • Elevated potentially pathogenic taxa (Bacteroides including B. fragilis group; Escherichia-Shigella; Ruminococcus gnavus; Ruminococcus torques; Streptococcus; Enterococcus) associated with dysbiosis and heightened symptom intensity through inflammatory signaling.
  • Altered carbohydrate fermentation and luminal gas production due to dysbiosis increases luminal distension and gas-related bloating, contributing to constipation–diarrhea switching.
  • Disrupted microbiome-derived metabolites, especially SCFAs like butyrate and propionate, may impair colonocyte health and motility regulation, amplifying urgency and stool irregularity.
  • Gut–brain axis and immune signaling: microbial byproducts can modulate nerve signaling and stress-responsive circuits, increasing visceral hypersensitivity and symptom flares with stress or sleep changes.
  • Testing-guided, personalized microbiome-targeted interventions: using microbiome results to tailor soluble fiber types and prebiotic strategies to rebalance fermentation and stabilize stool form.
Take a Gut Microbiome Test for IBS-M Insights Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Irritable bowel syndrome (IBS)

IBS-M (Irritable Bowel Syndrome—Mixed bowel habits) is a common functional gastrointestinal disorder where people experience alternating symptoms of constipation and diarrhea, often alongside cramping abdominal pain, bloating, urgency, and mucus in the stool. Unlike inflammatory bowel diseases, IBS-M doesn’t typically show structural damage or consistent inflammatory lesions on standard testing, which is why the condition is increasingly understood through gut–brain and microbiome-related mechanisms. Symptom patterns can fluctuate with stress, sleep changes, hormones, medications, infections, and certain foods—suggesting that internal gut signaling and ecosystem balance play a major role.

Your gut microbiome (the trillions of microbes living in the intestines) helps digest fibers and produce compounds that support the gut lining, regulate immune activity, and influence gut motility and sensation. In IBS-M, researchers often observe “dysbiosis,” meaning a shift in microbial composition and/or function compared with healthier individuals. This may affect fermentation patterns, gas production, short-chain fatty acid balance, gut barrier integrity, and the sensitivity of intestinal nerves—contributing to bloating and pain. Dysbiosis can also interact with the gut–brain axis via neural, hormonal, and immune pathways, potentially amplifying visceral hypersensitivity and altering how the nervous system interprets gut signals.

Practical microbiome-focused steps can be supportive for IBS-M symptom relief, particularly when tailored to your triggers. Approaches often include optimizing fiber type and dose (e.g., gradually increasing soluble fibers while being mindful of fermentable triggers), using evidence-informed diet strategies, managing stress and sleep to reduce gut–brain signaling disruption, and considering targeted interventions after identifying personal food and symptom patterns. Because IBS-M symptoms span both constipation and diarrhea, balancing stool-forming effects (through gut-friendly substrates that encourage beneficial microbial activity) while avoiding over-fermentation is key. Many people benefit from a structured plan—sometimes with clinician guidance—aimed at improving microbial function and reducing dysbiosis-related symptom drivers.

  • Bloating and abdominal distension
  • Abdominal pain or cramping
  • Constipation (inconsistent, difficult, or infrequent stools)
  • Diarrhea (loose or urgent stools)
  • Alternating constipation and diarrhea (mixed bowel habit)
  • Urgency and incomplete evacuation
  • Mucus in stool
Take a Gut Microbiome Test for IBS-M Insights Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

IBS-M — mixed bowel habit IBS

This information is relevant for people with IBS-M (irritable bowel syndrome with mixed bowel habits)—especially if you experience alternating constipation and diarrhea along with cramping abdominal pain, bloating, urgency, or mucus in your stool. It’s also a good fit if your symptoms fluctuate with stress, sleep changes, hormonal shifts, after infections, or in response to specific foods, since these patterns suggest gut–brain and microbiome-related influences rather than persistent structural damage.

It’s particularly relevant if you suspect that the gut microbiome plays a role in your day-to-day symptoms—for example, if certain meals trigger gas, distension, or urgency, or if you notice that stool form and frequency swing after dietary changes. IBS-M often involves “dysbiosis,” meaning differences in the composition and/or function of gut microbes that can affect fermentation balance, short-chain fatty acid production, gut barrier integrity, and intestinal nerve sensitivity—contributing to both bloating/pain and inconsistent bowel habits.

This content is also relevant if you’re looking for practical, microbiome-informed strategies to improve symptoms while balancing constipation and diarrhea. It’s aimed at people who want a more structured approach to diet (such as optimizing fiber type and dose thoughtfully), lifestyle factors (stress and sleep support for gut–brain signaling), and—when appropriate—personalized interventions guided by symptom and trigger tracking. If you’re dealing with urgency, incomplete evacuation, or mucus alongside mixed stool patterns, this is designed to help you understand why targeted changes may support more stable digestion and bowel regularity.

IBS-M (irritable bowel syndrome with mixed bowel habits) falls under the broader umbrella of irritable bowel syndrome (IBS), which affects a substantial share of the population. Overall IBS prevalence is commonly estimated at about 10–15% worldwide, with rates varying by region and study method. IBS is therefore one of the most common functional gastrointestinal disorders, and many sufferers experience a pattern consistent with IBS-M—alternating constipation and diarrhea—along with bloating, cramping, urgency, and mucus in the stool.

Within IBS, subtypes are often categorized by stool pattern (including mixed bowel habit). While exact subtype proportions vary across studies, IBS-M is frequently reported as a significant fraction of all IBS cases (commonly around one quarter to one third). That means that, in a population where IBS affects roughly 10–15%, the IBS-M phenotype may correspond to an approximate prevalence on the order of ~2.5–5% of people overall, depending on the dataset and diagnostic criteria used.

IBS symptoms (including the mixed constipation/diarrhea pattern typical of IBS-M) are also known to cluster in particular demographic groups, and many individuals are undiagnosed—so real-world prevalence is often higher than rates captured in clinical settings. Because IBS is a functional disorder without structural inflammatory lesions, prevalence estimates rely on symptom-based criteria (such as Rome diagnostic frameworks), which can produce differences between studies. Still, the consistent takeaway is that IBS-M is common: millions of people experience recurring bloating, abdominal pain, urgency, mucus, and alternating stool consistency, making it a major cause of GI morbidity despite the absence of inflammatory bowel disease pathology.

Take a Gut Microbiome Test for IBS-M Insights Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome & IBS-M: Mixed IBS and How Your Gut Bugs Influence Symptoms

IBS-M (mixed bowel habit IBS) is strongly connected to the gut microbiome through effects on fermentation, gas production, gut barrier function, immune signaling, and intestinal motility. In many people with IBS-M, researchers find microbial “dysbiosis,” meaning changes in which microbes are present and—just as importantly—how they function. These shifts can alter the balance of microbial metabolites such as short-chain fatty acids (SCFAs), which normally support colon health and help regulate how the gut moves and senses contents. When this metabolic balance is disrupted, it can contribute to core IBS-M symptoms like bloating, abdominal distension, and cramping.

The gut–brain axis provides another key mechanism linking microbiome changes to symptoms. Microbial byproducts and fermentation patterns can influence inflammation-like signaling and the communication between the gut lining and the nervous system, potentially increasing visceral hypersensitivity (the tendency for normal gut activity to feel painful or urgent). This may help explain symptom features such as urgency, incomplete evacuation, and mucus in the stool, which often fluctuate with stress, sleep changes, infections, and hormonal shifts—factors that can also reshape microbial communities and their activity. As the nervous system interprets gut signals more intensely, alternating constipation and diarrhea can become more prominent.

Because IBS-M involves both constipation and diarrhea, microbiome-linked strategies often focus on restoring a more stable microbial ecosystem and supporting stool-forming balance without triggering excess fermentation. Tailoring dietary fiber type and dose (often emphasizing gradually increased soluble, gut-tolerant fibers) can feed beneficial microbes that produce health-supporting metabolites while minimizing the gas and distension that can come from highly fermentable triggers. Over time, improving microbial function alongside gut–brain stability may reduce dysbiosis-related symptom drivers, helping to manage alternating bowel habits, bloating, and abdominal pain.

Take a Gut Microbiome Test for IBS-M Insights Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and IBS-M — mixed bowel habit IBS

  • Fermentation and gas production: Microbiome shifts change how carbohydrates are fermented in the colon, altering gas output and luminal osmotic effects that drive bloating, distension, and cramping in IBS-M.
  • Short-chain fatty acid (SCFA) balance: Dysbiosis can reduce or destabilize SCFA-producing microbial functions (e.g., butyrate/propionate), weakening colon fuel support for barrier maintenance and affecting stool consistency and motility.
  • Gut barrier function and permeability: Microbial metabolites and immune-modulating signals influence tight junction integrity and mucus layer health; impaired barrier signaling can amplify IBS symptoms through low-grade inflammation-like pathways.
  • Immune signaling and inflammatory tone: Altered microbial metabolites can modulate innate/adaptive immune responses and cytokine signaling, contributing to symptom flares (pain, urgency, mucus) even without overt inflammatory bowel disease.
  • Visceral hypersensitivity via the gut–brain axis: Microbial byproducts and metabolite patterns can affect afferent nerve signaling and stress/inflammation-like pathways, increasing pain perception and urgency during normal gut activity.
  • Intestinal motility regulation: Microbiome-derived signals (metabolites, neurotransmitter-like compounds, bile acid transformations) can influence enteric nervous system activity and motility patterns, supporting the alternating constipation/diarrhea pattern in IBS-M.

In IBS-M (mixed bowel habit IBS), the gut microbiome can become functionally “off-balance,” shifting how dietary carbohydrates are fermented in the colon. When microbial fermentation produces relatively more gas or other fermentation byproducts, this can increase luminal distension, trigger bloating, and amplify cramping. These same fermentation changes can also alter osmotic forces in the gut, contributing to unstable stool consistency and the alternating constipation–diarrhea pattern typical of IBS-M.

Microbiome-driven metabolite changes—especially short-chain fatty acids (SCFAs) such as butyrate and propionate—may further destabilize symptoms. SCFAs normally help nourish colon cells, support gut barrier integrity, and help regulate motility and visceral signaling. If microbial communities lose the capacity to generate these protective metabolites (or produce an imbalanced mix), the colon lining can become more vulnerable and stool form and transit can become harder to regulate, worsening urgency, incomplete evacuation, and mucus-related symptoms.

Through the gut–brain and immune interfaces, microbiome alterations can increase symptom intensity even without overt inflammatory bowel disease. Microbial metabolites can influence tight junctions, mucus layer health, and immune signaling tone, potentially promoting low-grade inflammation-like pathways that heighten sensitivity. At the same time, gut-derived byproducts and altered metabolite patterns can affect afferent nerve signaling and stress-response circuitry, driving visceral hypersensitivity—so normal gut activity feels painful or urgent. Microbiome signals can also modulate enteric nervous system function and bile acid transformation, which together can reinforce alternating motility patterns seen in IBS-M.

Take a Gut Microbiome Test for IBS-M Insights Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In IBS-M (mixed bowel habit IBS), studies often describe a microbiome that is less stable and functionally imbalanced rather than simply “more” or “less” diverse. The common theme is altered fermentation behavior—changes in how gut microbes break down dietary carbohydrates can shift luminal gas production and other byproducts, promoting distension and bloating. These functional shifts can also influence osmotic dynamics in the intestinal lumen, contributing to unstable stool consistency and the alternating constipation–diarrhea pattern typical of IBS-M.

Microbial metabolite output is frequently a key differentiator, especially short-chain fatty acids (SCFAs) like butyrate and propionate. When SCFA-producing capacity or the balance of these metabolites is disrupted, the colon lining may receive less support for barrier integrity and normal mucus-layer maintenance. Because SCFAs also help regulate motility and visceral signaling, an imbalanced metabolite profile can amplify symptoms such as cramping, urgency, and incomplete evacuation, and may contribute to mucus-related changes seen during symptom flares.

Beyond fermentation and metabolites, IBS-M is also linked to gut–brain and immune interface changes that are shaped by microbial activity. Microbial products can affect tight junction function, mucus tone, and immune signaling pathways in ways that mimic low-grade inflammatory signaling without overt inflammatory bowel disease. At the same time, altered microbial byproducts can modulate afferent nerve signaling and stress-response circuits, promoting visceral hypersensitivity—so normal intestinal contractions may be perceived as painful or urgent. Together, these gut-directed microbial effects can reinforce fluctuating motility patterns and symptom intensity in IBS-M.


Low beneficial taxa

  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Eubacterium rectale
  • Anaerostipes hadrus
  • Bifidobacterium longum
  • Bifidobacterium adolescentis
  • Akkermansia muciniphila


Elevated / overrepresented taxa

  • Bacteroides (including Bacteroides fragilis group)
  • Escherichia-Shigella
  • Ruminococcus gnavus
  • Ruminococcus torques
  • Streptococcus
  • Enterococcus


Functional pathways involved

  • Carbohydrate fermentation and luminal gas production pathways (incl. divergent fermentation of FODMAPs) driving bloating and distension
  • Short-chain fatty acid (SCFA) biosynthesis pathways—especially butyrate/propionate generation and utilization impacting barrier function and mucus maintenance
  • Osmotic and luminal water regulation pathways mediated by microbial metabolite profiles (e.g., altered fermentation end-products affecting stool consistency)
  • Bile acid metabolism and secondary bile acid signaling pathways that influence motility, secretion, and visceral sensitivity
  • Mucus layer degradation and mucin-utilization pathways (including shifts in Akkermansia-/mucin-related metabolic activity) affecting epithelial protection
  • Lipopolysaccharide (LPS) and other microbial component–driven immune activation/epithelial tight-junction modulation mimicking low-grade inflammatory signaling
  • Microbial modulation of gut–brain axis signaling pathways via microbial metabolites and signaling molecules (e.g., tryptophan/indole derivatives influencing afferent signaling and stress responses)
  • Microbial proteolysis and branched-chain amino acid fermentation pathways generating potentially pro-inflammatory/irritant metabolites linked to urgency and altered bowel habits


Diversity note

In IBS-M (mixed bowel habit IBS), research more often highlights changes in microbial function and stability than a simple increase or decrease in overall diversity. The microbiome may be less resilient—tending to shift more easily with diet changes, stress, infections, sleep disruption, and hormonal fluctuations—leading to alternating patterns of fermentation activity. These functional swings can affect how carbohydrates are broken down in the colon, influencing gas production and other fermentation byproducts that contribute to bloating, distension, and discomfort.

When microbial communities are functionally imbalanced, the downstream metabolite output—particularly short-chain fatty acids (SCFAs) like butyrate and propionate—may also become less consistent. SCFAs support the colonic barrier, help maintain the mucus layer, and participate in regulating motility and sensory signaling. In IBS-M, shifts in which microbes are present and, just as importantly, how they metabolize substrates can disrupt this metabolite balance, potentially weakening barrier support and contributing to cramping, urgency, and incomplete evacuation sensations.

Beyond fermentation and metabolites, diversity-related instability in IBS-M can coincide with changes at the gut–immune and gut–brain interface. Altered microbial signaling molecules can influence tight junction integrity and immune-like signaling pathways, supporting a low-grade inflammatory signaling pattern without meeting criteria for inflammatory bowel disease. In parallel, microbial byproducts may modulate afferent nerve activity and stress-response circuits, helping drive visceral hypersensitivity—so normal gut contractions feel more intense—reinforcing the mixed constipation–diarrhea pattern typical of IBS-M.


Take a Gut Microbiome Test for IBS-M Insights Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    For IBS-M, generic “one-size-fits-all” approaches often fail because the condition is driven by functional changes in fermentation and gut–brain signaling rather than a single, uniform problem. Many people with IBS-M have a microbiome that is less stable and functionally imbalanced, meaning the microbes may ferment carbohydrates differently, produce different metabolite profiles, and shift luminal gas and osmotic dynamics. As a result, interventions that work for IBS-C or IBS-D can backfire in IBS-M by either worsening distension (if they increase highly fermentable intake) or destabilizing stool consistency (if they disrupt fermentation balance), intensifying alternating constipation–diarrhea, cramping, and urgency.

    Another reason generic solutions underperform is that microbiome-linked symptoms are highly individualized and fluctuate with stress, sleep, infections, and hormonal changes—factors that can remodel microbial activity and metabolite output over time. Even when two people follow the same plan, their baseline microbial “function” (for example, SCFA-producing capacity like butyrate support for barrier and mucus maintenance) may differ, so the same dietary fiber, probiotic blend, or prebiotic dose can produce very different gas production, stool-form effects, and sensory responses. When visceral hypersensitivity and altered immune/epithelial signaling are involved, symptom perception may amplify changes that would otherwise be mild, making generic symptom control insufficient.

    Finally, many broad recommendations treat IBS-M as purely a digestive issue and don’t account for the gut–brain axis that translates microbial byproducts and gut signaling into pain, urgency, and incomplete evacuation sensations. Without tailoring to how a person’s gut responds to fermentation, motility shifts, and nervous-system sensitization, generic plans often miss the timing, tolerability, and fiber “type-and-dose” nuance needed to build a steadier microbial metabolite environment. In practice, this leads to stop–start adherence, persistent bloating, and continued alternating bowel habits because the underlying functional drivers aren’t consistently modulated.

  • Common mistakes

    • Using one-size-fits-all fiber advice (e.g., “increase fiber” universally) without matching fiber type and dose to IBS-M—often worsening gas/fermentation and distension, which amplifies bloating and pain.
    • Treating IBS-M as if it were either IBS-C or IBS-D rather than alternating mixed motility—choosing constipation- or diarrhea-targeted strategies that can destabilize fermentation and stool consistency.
    • Ignoring fermentation capacity and metabolite imbalance (SCFA/protein–carb fermentation shifts) and focusing only on symptom frequency/consistency, leading to interventions that don’t support a steadier luminal metabolite environment.
    • Overusing highly fermentable carbs (e.g., broad “healthy” substitutions, large legume portions, sugar alcohols) without timing guidance—can increase luminal gas/ osmotic effects and trigger urgency or constipation–diarrhea swings.
    • Assuming “more probiotics” or generic probiotic blends will help all IBS phenotypes—without considering strain-specific effects, baseline microbiome function, and whether the person is sensitive to fermentation changes or immune signaling modulation.
    • Skipping personalization around gut–brain axis triggers (stress, sleep, infections, hormonal cycles) that remodel microbial activity—leading to plans that fail during flare periods and produce inconsistent adherence.
    • Not accounting for visceral hypersensitivity and epithelial/immune signaling contributions—generic plans that aim only to normalize stool may still leave pain, urgency, and incomplete evacuation sensations unaddressed.
    • Changing multiple variables at once (diet + supplements + fiber) without structured re-challenge/titration—making it impossible to identify what worsens bloating or stool instability and causing stop–start treatment.

What to do

  • General support strategies

    For IBS-M (mixed bowel habit IBS), general microbiome-focused support centers on improving the stability of the gut ecosystem and stool-forming balance while avoiding dietary patterns that can intensify fermentation and gas. In practice, this often means gradually increasing gut-tolerant, soluble fiber (and finding an individualized dose) to help beneficial microbes produce protective metabolites such as short-chain fatty acids (SCFAs). Supporting more consistent SCFA production can favor healthier colonic function, help regulate how the intestine senses and moves contents, and reduce the cycle of bloating and cramping that can accompany microbial “dysbiosis.”

    Equally important is supporting gut–brain axis resilience, since IBS symptoms fluctuate with stress, sleep disruption, infections, and hormonal changes—factors that can both shift microbial activity and increase visceral hypersensitivity. Strategies that promote a calmer and more predictable gut signaling environment may include pairing diet changes with lifestyle routines that stabilize triggers (e.g., consistent meal timing, stress management, and adequate sleep). This can help reduce the likelihood that normal intestinal contractions feel painful, urgent, or incomplete, which is particularly relevant in IBS-M where bowel habits alternate.

    Finally, many people benefit from an approach that targets fermentative balance rather than simply “adding fiber.” This may involve prioritizing fiber types that are more tolerable, limiting highly gas-promoting triggers during flares, and using gradual, stepwise adjustments to diet so the microbiome can adapt. Over time, restoring more consistent microbial function and metabolite patterns can support smoother motility, improve stool consistency, and help lessen alternating constipation–diarrhea dynamics, bloating, and abdominal discomfort.

  • Lifestyle recommendations

    • Use a “low and slow” fiber approach: gradually increase soluble, gut-tolerant fibers (e.g., psyllium) to support more consistent stool form and reduce bloating/fermentation triggers.
    • Identify and limit personal fermentable triggers (common ones include high-FODMAP foods) and consider a structured low-FODMAP trial with dietitian guidance, then reintroduce to find tolerance levels.
    • Support regular gut motility with consistent meal timing and portion size; avoid long gaps between meals that can worsen urgency or cramping.
    • Practice stress and gut–brain calming strategies (e.g., CBT for IBS, mindfulness, paced breathing, or yoga) since symptom flares often track with stress and altered nervous system signaling.
    • Maintain good sleep hygiene and a stable routine, because sleep disruption can affect both bowel habits and microbiome patterns.
    • Stay hydrated and pair fiber increases with adequate fluids; if constipation alternates with diarrhea, aim for steady hydration rather than large “catch-up” volumes.
    • Keep gentle, regular physical activity (e.g., walking) to promote intestinal motility and help stabilize alternating bowel patterns.

  • Nutrition recommendations

    • Use gradually increased, soluble and gut-tolerant fiber (e.g., oats, chia, psyllium, carrots, zucchini), aiming for steady daily intake; avoid large, sudden increases that can worsen gas/bloating in IBS-M.
    • Identify and limit high-FODMAP fermentable carbs that commonly trigger mixed bowel symptoms (e.g., onion/garlic, wheat-based foods, certain fruits like apples/mango, legumes); consider a structured low-FODMAP trial with reintroduction to find personal triggers.
    • Prioritize gut-supportive prebiotic sources that are usually better tolerated in IBS-M (e.g., small servings of oats and psyllium, cooked/portion-controlled low-FODMAP vegetables) rather than high-dose inulin/chicory-heavy products.
    • Incorporate fermented foods in individualized portions (e.g., yogurt with live cultures, kefir, small amounts of kimchi/sauerkraut) to support microbial function; stop or reduce if fermentation worsens bloating or urgency.
    • Choose complex carbohydrates with steadier tolerance (e.g., rice, potatoes, quinoa, sourdough/spelt in some people) and keep meal portions consistent to reduce swings in fermentation and motility.
    • Support stool-forming balance and motility with hydration plus appropriate fiber type (e.g., psyllium can help both diarrhea and constipation for many); ensure adequate water intake when increasing fiber.
    • Reduce intake of gut-irritating dietary patterns that may amplify gut–brain signaling (e.g., excessive caffeine, alcohol, very fatty/greasy meals, large late meals) and eat regular meal timing to help stabilize symptoms.

  • Supplement considerations

    For IBS-M (mixed bowel habit), supplement strategies often aim to promote a more stable gut microbial ecosystem and reduce the symptom-driving downstream effects of dysbiosis. Because microbial fermentation patterns can influence gas production and stool consistency, many people benefit from interventions that support gut-tolerant carbohydrate handling (such as gradually introduced soluble fibers or fiber-forming supplements) while avoiding highly fermentable triggers that may worsen bloating. The goal is to encourage beneficial microbial metabolism—particularly short-chain fatty acid (SCFA) production—which supports colon barrier integrity, normal motility signaling, and overall gut epithelial health.

    Supplements may also be considered to help modulate gut–brain axis pathways that can amplify visceral sensitivity. Certain probiotics and/or targeted prebiotic fibers are used with the intent to shift microbial metabolite profiles and reduce inflammation-like signaling that can contribute to cramping, urgency, or the sensation of incomplete evacuation. Because IBS-M symptoms can fluctuate with stress, sleep disruption, infections, and hormonal changes—each of which can reshape the microbiome—stacking approaches often emphasize consistency and gradual adjustments, allowing the gut ecosystem and nervous system signaling to recalibrate.

    In practice, it’s also important to consider stool-form balance when choosing and titrating supplements. Some individuals may need support that favors stool formation during constipation-dominant phases (often with careful dosing of soluble fiber) while others may do better with options that reduce fermentation burden during diarrhea-dominant phases. Working with a clinician can help match supplement selection to symptom timing and tolerance, and ensure that any added microbiome-active agents (like probiotics or prebiotic fibers) are introduced slowly to minimize gas and distension.

  • Retesting / monitoring note

    For IBS-M (mixed bowel habit IBS), retesting is generally considered when symptoms change meaningfully, when initial results may no longer reflect the patient’s current gut ecosystem, or when a trial of microbiome-informed interventions (such as dietary fiber adjustments, probiotics, prebiotics, or gut-directed gut–brain strategies) is started and needs objective follow-up. Because gut microbial composition and functional activity can shift with diet, stress, sleep, infections, travel, antibiotics, and hormonal changes, retesting is most useful when it’s timed after a consistent routine has been in place—often for several weeks—rather than during periods of flare or major behavioral changes.

    A practical retesting approach is to re-check stool-based markers (where used) that better reflect fermentation patterns, stool consistency trends, and microbial metabolic function rather than relying on a single snapshot. For example, if previous testing suggested dysbiosis linked to fermentation-driven symptoms (bloating, distension, cramping) or if stool-form variation is prominent, retesting can help determine whether interventions have shifted the functional balance toward more favorable short-chain fatty acid (SCFA) production and less gas-promoting fermentation. Where available, pairing microbial readouts with clinical symptom tracking (e.g., stool frequency/consistency using a validated scale and symptom severity logs) can clarify whether changes in microbial function align with reduced urgency and improved evacuation.

    Retesting is also recommended for “decision points” in management—such as after ruling out red flags and confirming that symptoms remain consistent with IBS-M, or when alternating constipation/diarrhea persists despite first-line dietary and lifestyle changes. In these cases, follow-up testing can guide whether to continue, modify, or stop specific microbiome-targeted strategies (like soluble, gradually titrated fibers that are better tolerated in IBS-M, or carefully selected strains if probiotics were used). The goal of retesting is not to chase lab values, but to validate whether the gut ecosystem is stabilizing in a way that supports motility, barrier function, and gut–brain signaling—mechanisms closely tied to IBS-M symptom drivers.

The importance of gut microbiome testing

  • Why testing matters

    Gut microbiome testing matters for IBS-M because IBS-M symptoms can reflect more than just “normal” bowel changes—they often involve shifts in which microbes are present and, crucially, how well they ferment, produce metabolites, and interact with the gut barrier. When microbial communities become imbalanced (often described as dysbiosis), the balance of gut metabolites such as short-chain fatty acids (SCFAs) may change, which can influence colon health, gut motility, and the tendency toward bloating or cramping. Testing can help clarify whether your symptom pattern aligns with fermentation or metabolic imbalances that may contribute to alternating constipation and diarrhea.

    Testing can also provide clues about gut–brain axis factors that affect symptom severity in IBS-M. Microbial byproducts can influence immune signaling and the way the nervous system interprets gut activity, potentially contributing to visceral hypersensitivity (feeling discomfort or urgency more intensely than expected). Because IBS-M often fluctuates with stress, sleep changes, infections, and hormonal shifts—each of which can alter the microbiome—understanding your current microbial profile can help explain why symptoms may be triggered or amplified at certain times.

    Finally, microbiome results can make treatment and diet changes more targeted. Since IBS-M involves both stool looseness and incomplete evacuation or constipation-like periods, strategies often focus on restoring a more stable microbial ecosystem and improving stool-forming balance without triggering excess gas. Microbiome testing can guide whether a personalized approach to fiber type (e.g., more soluble, gradually increased options), prebiotic support, or other microbiome-targeted interventions may be more likely to support symptom control, rather than relying solely on trial-and-error.

  • How InnerBuddies helps

    For IBS-M (mixed bowel habit IBS), the InnerBuddies test can help you connect your symptoms to gut-microbiome patterns that go beyond “good” or “bad” bacteria. IBS-M is often linked to functional shifts in the microbiome—how microbes ferment dietary substrates, which metabolites they generate (including short-chain fatty acids that support colon health), and how these changes may contribute to bloating, cramping, and alternating constipation and diarrhea. By reviewing your microbiome profile, the test can offer insight into whether your current balance appears tilted toward higher gas/fermentation activity or toward reduced metabolite support that can affect stool consistency and gut comfort.

    InnerBuddies can also support a gut–brain axis perspective that’s especially relevant in IBS-M, where stress and other fluctuating triggers often amplify visceral sensitivity. Microbial byproducts can influence immune signaling and the way the gut lining communicates with the nervous system, which may make normal bowel activity feel more painful or urgent. Seeing your microbiome-associated signals can help you understand potential drivers of symptom intensity and help explain why episodes may worsen around sleep disruption, stress, infections, or hormonal changes that can reshape microbial communities.

    Most importantly, the InnerBuddies results can make next-step interventions more targeted than trial-and-error. Since IBS-M management often focuses on improving stool-forming balance while minimizing distension from overly fermentable triggers, the test can guide more personalized dietary and microbiome-support choices—such as gradually increasing gut-tolerant, soluble fiber types and aligning prebiotic or fiber strategy with your fermentation profile. Over time, this functional personalization may help support a more stable microbial ecosystem and improve mixed bowel symptoms more consistently.

Medical Evidence

  • Scientific evidence level

    2 [weak/emerging but inconsistent]

  • Clinical relevance note

    At present, the microbiome is best considered a plausible contributing factor rather than a clinically actionable driver for IBS-M. The strongest human signal is an association between “IBS overall” and microbiome differences, but IBS-M-specific, reproducible, and causally informative microbiome signatures are not established. The field is also constrained by methodological variability (16S vs metagenomics, DNA extraction/storage effects, stool vs mucosal sampling, compositionality biases, and differing confounder control). These limitations weaken confidence that any specific taxa/community feature is reliably linked to IBS-M.

    From a practical clinical perspective, measuring the gut microbiome does not currently improve real-world prevention, diagnosis, treatment selection, or monitoring for IBS-M beyond standard clinical assessment. Even when interventions (e.g., certain probiotics or dietary strategies) improve IBS symptoms in trials, the microbiome mechanisms are not consistently demonstrated, and IBS-M-specific response prediction is not validated. Therefore, while microbiome research may inform future stratified approaches (e.g., mechanistically guided dietary or microbial therapies), current evidence supports only hypothesis-generating links rather than validated clinical application for IBS-M.

Title Journal Year Link
Gut microbiota in irritable bowel syndrome: a systematic review and meta-analysis Frontiers in Microbiology 2017 View →
Gut microbiome and metabolome in irritable bowel syndrome: a multi-omics study Gastroenterology 2016 View →
Irritable bowel syndrome and the microbiome Nature Reviews Gastroenterology & Hepatology 2015 View →
Microbiota in irritable bowel syndrome: associations with symptoms, microbiota composition and function Nature Reviews Gastroenterology & Hepatology 2012 View →
Fecal microbiota in irritable bowel syndrome: a pilot study Gut Microbes 2012 View →

Frequently Asked Questions

    Qu'est-ce que le IBS-M ?
    Le IBS-M, ou syndrome de l’intestin irritable avec des habitudes intestinales mixtes, signifie que les selles alternent entre constipation et diarrhée, souvent accompagnées de crampes, ballonnements, urgence et mucus dans les selles. C’est une affection fonctionnelle et elle ne montre généralement pas de dommages structurels lors des examens standard.
    Quels sont les symptômes typiques du IBS-M ?
    Ballonnements et distension abdominale, douleur ou crampes abdominales, constipation, diarrhée, urgence et sensation d’évacuation incomplète, mucus dans les selles.
    En quoi le IBS-M diffère-t-il du IBS-D ou du IBS-C ?
    Le IBS-M présente à la fois constipation et diarrhée. Le IBS-D est principalement diarrhé, le IBS-C principalement constipation.
    Quelle est la fréquence du IBS-M ?
    Le IBS essentiel touche environ 10–15% de la population mondiale. Le IBS-M représente une part importante des cas de IBS (environ un quart à un tiers), soit environ 2,5–5% de la population. Les chiffres varient selon les critères.
    Qu’est-ce que la dysbiose du microbiome intestinal pour le IBS-M ?
    La dysbiose désigne un déséquilibre de la communauté microbienne qui peut influencer la fermentation, les métabolites, la barrière intestinale et la sensibilité nerveuse, contribuant ainsi aux symptômes.
    Comment le microbiome influence-t-il les ballonnements et les variations de selles ?
    Les changements de fermentation et de production de gaz, ainsi que les effets osmotiques, peuvent provoquer distension et variabilité de la consistance des selles.
    Qu’est-ce que les acides gras à chaîne courte (SCFA) et pourquoi sont-ils importants dans le IBS-M ?
    Les SCFA comme le butyrate et le propionate soutiennent la santé du côlon, l’intégrité de la barrière et la motilité; des déséquilibres peuvent aggraver les symptômes.
    Qu’est-ce que l’axe intestin-cerveau et quel est son rôle dans le IBS-M ?
    Les métabolites microbiens peuvent influencer les nerfs et la signalisation immunitaire du tube digestif, ce qui peut augmenter la perception de douleur et l’urgence.
    Quels tests peuvent montrer les changements du microbiome dans le IBS-M ?
    Des tests fécaux du microbiome peuvent cartographier les microbes et leur fonction, mais ils ne diagnostiquent pas. Ils peuvent aider à interpréter les motifs et guider la prise en charge.
    Comment les tests du microbiome peuvent-ils guider le traitement du IBS-M ?
    Les résultats peuvent aider à personnaliser le choix et la dose de fibres, les prébiotiques et d’autres mesures ciblant le microbiome pour améliorer l’équilibre des selles et réduire les gaz.
    Qu’est-ce que InnerBuddies et comment cela aide-t-il le IBS-M ?
    InnerBuddies est un test du microbiome qui relie votre profil microbien à vos symptômes IBS-M et à l’axe cerveau–intestin pour orienter les changements de mode de vie; ce n’est pas une cure.
    Quelles approches diététiques peuvent aider et comment commencer ?
    Envisagez d’ajouter progressivement des fibres solubles et d’utiliser des stratégies fondées sur des preuves, adaptées à vos besoins, parfois avec une approche FODMAP limitée sous supervision.
    Comment intégrer les fibres sans augmenter les gaz ?
    Commencez par de petites quantités de fibres solubles, augmentez lentement et surveillez la tolérance.
    Dois-je toujours essayer un régime pauvre en FODMAP ?
    Le régime pauvre en FODMAP peut aider certaines personnes; ce n’est pas adapté à tout le monde. Parlez-en avec un médecin ou un diététicien.
    Comment le stress, le sommeil, les hormones et les infections influent sur le IBS-M ?
    Ils peuvent modifier l’axe cerveau–intestin et le microbiome, déclenchant ou aggravant les symptômes.
    Le IBS-M peut-il être guéri ou est-il surtout géré ?
    La plupart des personnes gèrent les symptômes par l’alimentation, l’ajustement des fibres, la gestion du stress et des approches ciblées du microbiome. Il n’existe pas de cure universelle.
    Quels signes d’alerte nécessitent une consultation médicale ?
    Si les symptômes s’aggravent, s’il y a du sang dans les selles, une perte de poids involontaire, de la fièvre, une déshydratation sévère ou des douleurs fortes persistantes, consultez un médecin.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -